Profile snapshot
Quick facts
These fields are educational context only. Typical dose information is not dosing guidance.
- Type
- Synthetic ACTH(4-10)-derived heptapeptide
- Half-life
- Not established in U.S. labeling
- Typical dose
- Regional and study context only; no FDA-approved dose.
- Regulatory status
- No FDA-approved U.S. medicine identified
Current status
Semax is a regional and research-literature peptide topic, not an FDA-approved U.S. medicine. This educational profile is current as of May 31, 2026 and does not provide dosing, intranasal-use, compounding, or purchasing guidance.
Plain-English summary
Overview
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment sequence, commonly discussed in nootropic and neuroprotection contexts. The online marketing angle is often much stronger than the accessible clinical evidence. [1][2]
The most grounded way to read Semax claims is to separate preclinical neurotrophic research, regional stroke literature, and consumer nootropic claims. These are different evidence categories and should not be collapsed into one promise. [1][2][3][4]
Neurotrophic signaling
Mechanism
A frequently cited mechanistic theme is BDNF. Rat work reported that intranasal Semax increased brain-derived neurotrophic factor protein in the basal forebrain and suggested specific binding sites in that region. [1]
Other animal studies have examined neurotrophin gene expression and related pathways. These data are biologically interesting, but BDNF changes in animal tissue do not prove memory, focus, recovery, or mood benefits in healthy human users. [1][2][4]
Clinical context
Human Evidence
Human Semax research is often discussed in stroke and rehabilitation contexts. A PubMed-indexed Russian-language article reports Semax use at different stages of ischemic stroke, with keywords including Barthel index, BDNF, rehabilitation, and stroke. [3]
A 2020 functional-connectivity study included Semax, Selank, and placebo in 52 healthy participants. It measured resting-state fMRI connectivity rather than real-world cognitive performance, which limits how far readers should extend the findings. [5]
Risk context
Safety Context
Because Semax does not have a U.S. prescribing label, there is no FDA-approved indication, contraindication list, adverse-event table, or standardized route for a U.S. Semax product.
Metal-binding and cell-biology studies can inform basic chemistry and mechanism, but they do not replace human safety data. For research-market products, identity, purity, sterility, excipients, and route remain separate concerns. [6]
Consumer claims about focus, brain fog, stroke recovery, or neuroprotection should be treated cautiously unless they identify the study population, endpoint, route, comparator, and regulatory context. [1][3][5]
No protocol guidance
Storage and Handling Limits
Peptides Defined does not provide Semax dosing, nasal-use instructions, injection instructions, mixing instructions, or storage protocols. Research literature and product listings are not a substitute for an approved label.
If a seller product is marketed as Semax, product-specific COA review is still separate from clinical evidence review. A molecule name alone is not proof of identity, purity, strength, or suitability.
FAQ
Is Semax FDA-approved?
No FDA-approved U.S. Semax medicine is covered by this profile. Regional clinical use or research literature should not be treated as U.S. approval.
Does Semax increase BDNF?
Animal studies have reported BDNF-related changes after Semax exposure. That supports a mechanistic research angle, but it does not prove human nootropic outcomes. [1][2]
Is Semax proven for stroke recovery?
Semax has regional human literature in ischemic stroke contexts, but readers should be careful about language, study design, comparator, and generalizability before turning that into a treatment claim. [3]
Does this page give Semax dosing?
No. This page does not provide dosing, nasal-use instructions, injection instructions, compounding guidance, or individualized medical advice.
References
-
[1] Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain
Journal of Neurochemistry / PubMed. April 2006.
https://pubmed.ncbi.nlm.nih.gov/16635254/ -
[2] The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo
PubMed. Record accessed May 31, 2026.
https://pubmed.ncbi.nlm.nih.gov/14556513/ -
[3] The efficacy of semax in the treatment of patients at different stages of ischemic stroke
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova / PubMed. 2018.
https://pubmed.ncbi.nlm.nih.gov/29798983/ -
[4] Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10
PubMed. Record accessed May 31, 2026.
https://pubmed.ncbi.nlm.nih.gov/17353092/ -
[5] Functional Connectomic Approach to Studying Selank and Semax Effects
Doklady Biological Sciences / PubMed. January 2020.
https://pubmed.ncbi.nlm.nih.gov/32342318/ -
[6] Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties
Journal of Inorganic Biochemistry / PubMed. November 2016.
https://pubmed.ncbi.nlm.nih.gov/27586814/